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Non-invasive detection of adeno-
associated viral gene transfer using 
a genetically encoded CEST-MRI 
reporter gene in the murine heart
Shelby Meier  1,2, Assaf A. Gilad3,4,5,6,7, J. Anthony Brandon1, Chenghao Qian1, Erhe Gao8, 
Jose F. Abisambra1,2 & Moriel Vandsburger9
Research into gene therapy for heart failure has gained renewed interest as a result of improved safety 
and availability of adeno-associated viral vectors (AAV). While magnetic resonance imaging (MRI) is 
standard for functional assessment of gene therapy outcomes, quantitation of gene transfer/expression 
relies upon tissue biopsy, fluorescence or nuclear imaging. Imaging of gene expression through the 
use of genetically encoded chemical exchange saturation transfer (CEST)-MRI reporter genes could be 
combined with clinical cardiac MRI methods to comprehensively probe therapeutic gene expression 
and subsequent outcomes. The CEST-MRI reporter gene Lysine Rich Protein (LRP) was cloned into an 
AAV9 vector and either administered systemically via tail vein injection or directly injected into the left 
ventricular free wall of mice. Longitudinal in vivo CEST-MRI performed at days 15 and 45 after direct 
injection or at 1, 60 and 90 days after systemic injection revealed robust CEST contrast in myocardium 
that was later confirmed to express LRP by immunostaining. Ventricular structure and function were 
not impacted by expression of LRP in either study arm. The ability to quantify and link therapeutic gene 
expression to functional outcomes can provide rich data for further development of gene therapy for 
heart failure.
Improved safety profiles and the availability of multiple serotypes of adeno-associated viral vectors (AAV) with 
distinct organ affinity1 have renewed interest in gene therapy approaches, particularly for cardiovascular dis-
ease2,3. Early clinical trials including the calcium upregulation by percutaneous administration of gene therapy 
in patients with cardiac disease (CUPID) trial that sought to restore cardiac function in heart failure patients via 
AAV1 mediated gene delivery often showed promise in early stage trials4 but did not provide definitive benefit 
in larger phase II trials5–7. Immuno-histochemical evidence from individuals who proceeded to cardiac trans-
plantation confirmed inadequate therapeutic gene expression in non-responders6,7. Important methodological 
questions including whether a different delivery scheme (e.g. route, dose, repeated administration, concentration 
of empty capsids) would have resulted in increased therapeutic gene expression, in terms of both magnitude and 
spatial distribution, and subsequent outcomes in such individuals remain unanswered. The ability to repeatedly 
quantify and correlate the degree and distribution of therapeutic gene expression to functional outcomes on an 
individual basis would provide a rich data set that can be used to refine the preparation, execution, and continued 
monitoring in cardiac gene therapy.
Quantitative measurement of gene expression following viral delivery is has been performed using fluores-
cent/ bioluminescent whole body imaging in small animals1,8,9. However, such techniques are not scalable to 
large animal models or clinical settings. Alternative reporter imaging techniques including sodium-iodide (Na/I) 
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transporter imaging using single photon emission computed tomography (SPECT) require radioactive probes10. 
Subsequently, clinical monitoring of gene expression patterns requires either undesirable repeated radiation 
exposure or extrapolation from repeated biopsies5. Both requirements represent a substantial barrier in indi-
viduals with heart failure that can be addressed by non-invasive imaging. Magnetic resonance imaging (MRI) is 
used clinically for assessment and quantification of cardiac structure and function11. Additionally, quantitative 
MRI techniques are now routinely used to measure important outcomes of gene therapy including tissue perfu-
sion, contractile function, and fibrosis12. Molecular MRI with chemical exchange saturation transfer (CEST) is 
an emerging approach for the multi-color detection of molecular probes and reporter genes that are selectively 
imaged with tunable radiofrequency energy at distinct resonant frequencies13–15. Recently a number of CEST 
active genetically encoded reporter proteins16–20 including the Lysine Rich Protein (LRP), which is comprised 
of 200 lysine residues and generates CEST contrast when excited with RF energy tuned to 3.76 parts per million 
(ppm) offset from water, have been developed and utilized for in vivo cell tracking and for quantitative imaging of 
oncolytic virotherapy in stationary organs18,21,22.
The application of genetically encoded CEST-MRI reporters for imaging in cardiac gene therapy could enable 
the immediate superimposition of quantitative in vivo imaging of gene expression patterns with functional out-
comes at the spatial resolution of MRI and without the need for biopsy or radioactive tracers. We have developed 
and applied a specialized cardiac CEST-MRI approach for non-invasive imaging of fibrosis23, creatine metabo-
lism24, and for quantitative cardiac cell tracking in small animals24,25. In the current study we cloned the Lysine 
Rich Protein into an AAV9 vector and measured regional and time dependent changes in CEST-MRI contrast 
following either direct injection into the ventricular wall, or systemic administration via the tail vein.
Results
Cell Transfection. The reporter gene construct contained the Lysine Rich Protein, enhanced green fluo-
rescent protein (eGFP), and the V5 tag under control of the CMV promoter (pAAV9-CMVprom::LRP-IRES_
eGFP-V5). Transfection of isolated HEK293T cells resulted in green fluorescence of transfected cells (Fig. 1). 
Western blot analysis of homogenized cells revealed strong staining for V5 in cells transfected with the AAV9 
construct.
Direct injection of AAV9-LRP regionally elevates CEST contrast. In the first study arm, we sought 
to determine whether injection of an AAV9 vector encoding for LRP into a defined region of left ventricular 
myocardium would result in regionally elevated CEST contrast. Mice undergoing intra-myocardial injection of 
AAV9 were randomized to receive either AAV9 containing Lysine Rich Protein and V5 (n = 9) or an empty AAV9 
vector (n = 6). Cardiac CEST-MRI was performed at 15 and 45 days after injection to probe for contrast generated 
by LRP expression. Representative cardiac CEST images and corresponding MTRasym maps are shown in Fig. 2 
for both vectors.
Immuno-fluorescent staining was used to guide the definition of regions of interest on MR images for mice 
receiving AAV-LRP. For mice receiving the empty AAV9 vector, hematoxylin and eosin staining was used to 
identify the location of the needle track in the imaged slice, and the corresponding region of myocardium was 
segmented on MR images. While CEST contrast measured in the myocardium of mice receiving an empty AAV9 
vector was uniformly low (0.63 ± 2.0% Day 15, 1.96 ± 1.86% Day 45), the average MTRasym value within V5-LRP 
expressing regions was significantly elevated at both 15 (11.6 ± 4.4%) and 45 (10.2 ± 3.9%) days after injection 
(Fig. 3). Prior to AAV9 administration the average myocardial MTRasym values in the same regions of interest 
among all mice were 0.74 ± 2.13%. The application of the same region of interest over time among the AAV9-LRP 
cohort revealed temporally heterogeneous dynamics of Lysine Rich Protein CEST contrast amongst mice (Fig. 3).
Systemic injection of AAV9-LRP heterogeneously elevates CEST contrast. In the second arm of 
this study we sought to probe the time-course of cardiac CEST contrast following the systemic administration 
Figure 1. Transfection of HEK293T cells using the AAV9 vector encoding for eGFP, V5 and LRP. (Left) 
Phase contrast image of HEK293T cells and (middle) corresponding fluorescence microscopy image showing 
expression of eGFP. (Right) Western blot of cell homogenates for cells infected with AAV9-LRP (+) or control 
uninfected cells (−) demonstrates positive staining for the V5 epitope. The position of the LRP-V5 band with 
respect to the ladder is influenced by the strongly positive charge of LRP compared to other proteins of similar 
size.
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of AAV9 virus containing LRP. Mice were randomized to receive either AAV9 encoding LRP-IRES-eGFP-V5 
(n = 13), an empty AAV9 vector (n = 9), or saline (n = 7), delivered intravenously through the tail vein. Cardiac 
CEST MRI was performed in one mid-ventricular slice at one, sixty, and ninety days after administration. 
Representative images and corresponding maps of MTRasym from data acquired sixty days after administration 
are shown in Fig. 4.
Figure 2. Direct injection of AAV9 encoding for the Lysine Rich Protein results in regionally specific CEST 
contrast at 45 days after injection. (A) Cardiac CEST image acquired following radiofrequency saturation at 
−3.76ppm (control excitation). The site of injection is indicated by the red arrow. (B) Corresponding cardiac 
CEST image acquired following saturation at +3.76ppm. The excitation of LRP and subsequent exchange of 
saturated magnetization results in a reduced steady state longitudinal magnetization, and thus signal intensity, 
in voxels containing LRP expressing cells. (C) CEST contrast calculated as MTRasym from images A and B 
is elevated in the septum and inferior wall about the inferior right ventricular insertion point (red arrow). 
Slight elevations in MTRasym are observed in the interventricular septum. (D) Immuno-fluorescent staining 
of the corresponding tissue section confirms expression of the LRP-V5 construct in the same tissue regions as 
observed using CEST MRI. (E) Injection of an empty AAV9 vector did not result in observable CEST contrast 
or (F) positive staining of isolated tissue sections. Higher magnification images of D and F are shown in 
Supplemental Figure 1.
Figure 3. Time-course of regional changes in CEST contrast. Box and whisker plots summarize measurement 
of regional MTRasym values at 15 and 45 days after intra-myocardial injection of either AAV9 encoding for LRP 
or an empty AAV9 vector (grey bar represents the mean value). At both time points, MTRasym values within 
tissues that positively stained for V5 expression were significantly higher than corresponding regions of interest 
from mice receiving an empty AAV9 injection. While mean MTRasym values in the AAV9-LRP group were not 
substantially different between days 15 and 45, (Right) individual mice within the AAV9-LRP group (squares) 
demonstrated diverse changes in MTRasym values between both time-points. The corresponding values in mice 
receiving empty AAV9 vectors (circles) were consistent over time.
www.nature.com/scientificreports/
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The intravenous injection of AAV9 encoding for LRP-IRES-eGFP-V5 resulted in significant CEST contrast in 
the hearts of mice by sixty days after administration as compared to corresponding measurements acquired one 
day after administration (Fig. 5). In contrast, neither saline nor an empty AAV9 virus used as controls resulted 
in similar changes in CEST contrast at any point during the imaging time-course (Fig. 5). Excision and coimmu-
noprecipitation of hearts at ninety days after injection confirmed expression of LRP-V5 in mice receiving AAV9 
encoding for LRP and V5 (Fig. 5). Comaprison of mean MTRasym values to corresponding quantification of V5 
expression from whole heart homogenates demonstrated a promising trend when compared to quantification 
by western blot analysis (Pearson’s ρ = 0.5, p = 0.14, Figure S3) and a significant correlation when compared to 
quantification from co-immunoprecipitation (Pearson’s ρ = 0.67, p = 0.04, Figure S3).
Impact of LRP expression on cardiac structure, function, and hemodynamics. The impact of LRP 
expression on cardiac structure was examined by measuring mid-ventricular end-diastolic septal thickness and 
the ratio of septal thickness to inner left ventricular radius (h/r ratio). Myocardial systolic function was assessed 
as peak fractional shortening. Neither the direct injection nor the systemic administration of AAV9-LRP resulted 
in changes in left ventricular structure or function at any point in the observed time-course (Fig. 6). Heart rate 
data for the systemic (Table S1) and direct (Table S2) administration protocols can be found in the supplemen-
tal data section. Within the systemic administration study heart rates were similar at one and sixty days after 
viral administration, but elevated in mice receiving saline compared to either AAV9 group at ninety days after 
Figure 4. Representative maps of MTRasym at 60 days after tail vein injection of either saline, empty AAV9, 
or AAV9-LRP. Myocardial MTRasym values remained low in mice receiving either saline or an empty AAV9 
vector. Among mice receiving AAV9-LRP, the average response resulted in a large number of voxels with 
elevated MTRasym across the heart. However, variability was observed in both the spatial pattern and magnitude 
of MTRasym elevation among mice receiving AAV9-LRP. This variability can be appreciated by comparing the 
MTRasym maps generated in mice with the lowest change in MTRasym over baseline levels (Minimum LRP), 
the group average changes in MTRasym over baseline (Average LRP), and the maximal change in MTRasym over 
baseline levels (Maximum LRP).
Figure 5. Systemic administration of AAV9-LRP. (A) Box and whisker plots of mean myocardial MTRasym 
values reveal a similar absence of CEST contrast 24 hours after intravenous injection of either AAV9 or saline 
(−1.6 ± 3.9% AAV9-LRP, −2.1 ± 2.74% AAV9-Empty, −0.65 ± 2.3% Saline). In mice receiving AAV9-LRP the 
mean myocardial MTRasym values increased substantially by Day 60 (4.9 ± 4.3% AAV9-LRP, −1.0 ± 2.3 AAV9-
Empty, −1.87 ± 2.1% Saline) and remained elevated at 90 days after injection (3.4 ± 3.1% AAV9-LRP, −0.6 ± 2.3 
AAV9-Empty, 0.1 ± 2.3% Saline) in comparison to Day 1. (B) Representative western blots of mouse heart 
samples using a V5 antibody confirmed expression of LRP-V5 in mice exposed to the AAV9-LRP construct at 
Day 90. The corresponding full -length gels can be found in Supplemental Figure 2. Co-IP gels demonstrating 
reduced non-specific binding can be found in Supplemental Figure 2. (*P < 0.05 vs. Day 1 in same group, 
_P < 0.05 between groups at same time point).
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administration. Within the direct injection protocol, heart rates were similar between AAV9 cohorts at both time 
points, though both groups showed significant increases in heart rate between time points.
Discussion
Among the many challenges that remain in the field of cardiac gene therapy using viral delivery, the inability to 
non-invasively quantify the extent, magnitude and duration of therapeutic gene expression without radiation 
based imaging or biopsy approaches remains a significant obstacle. As a result, it is difficult to determine whether 
the eventual fruition or absence of functional outcomes is due to limited delivery, abrogated expression, or a lack 
of therapeutic effect despite adequate expression. In this study we demonstrated the ability to serially image lon-
gitudinal changes in CEST contrast generated by expression of a genetically encoded CEST-MRI reporter gene 
in the mouse heart following AAV9 mediated delivery. The results of this study have several important potential 
future clinical implications. First, patient examination with CEST-MRI after initiation of viral gene therapy could 
allow for whole heart, radiation free and non-invasive assessment of initial gene delivery and time dependent 
expression patterns. Second, since the contrast generated by expression of CEST active reporter genes is selec-
tively ‘turned on’, measurement of functional outcomes of gene therapy including tissue thickness, contractile 
function, fibrosis, and perfusion can be assessed in series in the same imaging session. Subsequently, the coupling 
of gene expression patterns and therapeutic outcome can be determined on an individualized basis. This is in 
contrast to reporter gene methods for cardiac MRI that have used either expression of iron regulatory proteins 
such as Ferritin26 or required administration of iron oxide nanoparticles targeting genetically encoded membrane 
reporter proteins27. In both cases, assessment of gene expression requires substantial T2/T2* contrast that limits 
the capacity to acquire additional meaningful outcome measurements in the same tissue region. Finally, while 
we did not examine off-target expression of the Lysine Rich Protein, CEST-MRI is already applied to additional 
organs including the brain, lungs, kidneys, and skeletal muscle. Combined measurement across organ systems 
can allow for individualized treatment planning that targets the optimal response in the heart while minimizing 
off target expression.
Pre-clinical studies of AAV9 mediated gene delivery to the heart have previously used either 
immuno-histochemical staining of isolated tissue sections or in vivo bioluminescence imaging to probe for gene 
expression patterns1,9,28–31. In agreement with prior studies that utilized serial bioluminescence imaging following 
systemic AAV9 administration8,9,28, cardiac CEST contrast generated by LRP was heightened at both sixty and 
ninety days post administration compared to baseline levels. In a prior study by Prasad et al., systemic adminis-
tration of AAV9 through the jugular vein of 1 week old mice led to uniform expression of eGFP throughout the 
ventricular myocardium within 30 days9. In contrast, we observed spatially heterogeneous CEST contrast across 
the myocardium in mice receiving systemic injection of AAV9-LRP (Fig. 4). Similar spatial heterogeneity was also 
observed at 70 days after systemic injection of AAV9 by Werfel et al. upon staining of isolated tissue sections for 
the LacZ reporter28. Differences in observed patterns between studies may be attributed to the age of mice at time 
Figure 6. Measures of ventricular structure and function were unchanged by LRP expression status. In both 
the direct injection (left) and systemic administration (right) protocols ventricular structure as assessed by 
septal wall thickness and the ratio of wall thickness to the inner radius (h/r ratio) was not significantly different 
between hearts in which LRP expression was induced (LRP), empty vector (Empty, E.V.), and saline controls. 
Ventricular systolic function assessed as peak fractional shortening was similarly unchanged between groups 
and over time. Anesthesia was maintained using 1.5% isoflurane in oxygen. Mean and standard deviation values 
for all graphed components can be found in Supplemental Table 3.
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of exposure (1 week vs. 8 weeks Werfel et al. and current study), the promoters used to drive expression of the 
reporter gene (cTnT vs. CMV in current study), and route of administration (jugular vs. tail vein Werfel et al. and 
current study). Interestingly, the gradients in CEST contrast observed in most mice receiving AAV9-LRP seemed 
to follow a coronary distribution pattern (Fig. 5, Average LRP), suggesting heterogeneous delivery following 
intravenous administration. Similar concerns regarding non-uniform delivery following intravenous administra-
tion have been raised by others10,28,29. However, additional studies that directly compare regional CEST contrast 
to corresponding quantitative measures of tissue LRP levels are necessary to clarify whether these patterns are 
truly reflective of underlying LRP expression or represent a threshold level of LRP expression that is required 
for CEST detection. Regrettably, we utilized all of the heart tissue from this study arm after Day 90 to perform 
a co-immunoprecipitation assay in order to confirm expression of the V5 tag and are unable to examine the 
regional correlation between CEST contrast and LRP expression. However, correlation analysis between MTRasym 
at Day 90 and the V5 western and IP signals measured from whole heart homogenates demonstrated strong 
correlation between CEST-MRI contrast and underlying LRP expression (see Supplemental Figure 2). A direct 
correlation between CEST contrast and regionally constrained V5 western signals as part of future studies will 
more directly enable examination of the correlation between the molecular and the imaging system components. 
In addition, while we have previously shown that B0 inhomogeneity across the mouse heart is smaller than the 
bandwidth of the saturation pulse used to generate CEST contrast24,32, it is important to note that B1 inhomo-
geneity of the saturation pulse can lead to regional differences in observed CEST contrast that may not obscure 
underlying changes in LRP expression.
In comparison to the heterogeneous patterns observed following systemic administration, direct injection 
of AAV9-LRP into the myocardium produced robust CEST contrast about the site of injection (Fig. 2). This 
finding agrees with prior large animal models that used the Na/I transporter to examine the impact of delivery 
route on subsequent gene expression. Catheter based delivery into the myocardium of pigs by Moulay et al. pro-
duced robust contrast on SPECT/CT images, while contrast in the heart following intravenous administration 
was considerably attenuated10. In a prior study by Prasad et al., serial in vivo bioluminescence imaging following 
intra-myocardial injection of AAV9 in adult mice revealed a rapid increase in luciferase expression by 14 days 
after administration that thereafter remained comparatively constant until 42 days after injection8. In the current 
study the average CEST contrast measured in the same regions of interest over time in mice receiving a direct 
injection of AAV9-LRP was not significantly different as a group between 15 and 45 days post injection (Fig. 3). 
However, CEST contrast decreased in four mice and increased in two mice between time points. Differences 
in promoters (cTnT vs. CMV) and surgical techniques (open chest vs. pop out) may have contributed to the 
observed differences between our study and that of Prasad et al.8. Importantly, in vivo bioluminescence meas-
ures of average radiance represent a complex function of integrated luciferase expression over the entire heart 
combined with position dependent light scattering and attenuation. As such, changes in the spatial patterns and 
magnitudes of luciferase expression over time may be masked by measurement of the average radiance over the 
entire heart. In contrast, repeated measures of MTRasym in defined and maintained regions of interest provides 
anatomically specific quantitation of changes in CEST contrast generated by reporter gene expression. The capac-
ity to repeatedly make such measurements will be useful to applications that seek therapeutic gene expression 
in distinct regions of myocardium, e.g. restricted expression in border zone cardiomyocytes after myocardial 
infarction, but previously relied upon ex vivo tissue staining to confirm spatial localization.
The design of the current iteration of LRP raises several potential limitations to both the ultimate sensitivity 
of this method and to its clinical translation. For example, the repetitive nature of the LRP can lead to instability 
both at the transcriptional and translational level. Repetitions in the DNA can lead to recombination and exclu-
sion of fragment of the genes. This issue can be addressed by re-engineering and optimizing the DNA sequence as 
was done for the human protamine-133. At the protein level, replacement of some of the lysine residues in strategic 
location can minimize the charge and reduce cleavage by intracellular proteases. It is important to note that enzy-
matic cleavage of LRP into shorter peptides will not impact the total measured CEST contrast, because the con-
trast is not determined by the structure of the LRP but rather by the total number of exchangeable protons. Newer 
versions of LRP that are under development and utilize a more sophisticated design of the amino acid sequence to 
reduce the likelihood of enzymatic cleavage will boost the contrast generated by constitutive expression of LRP. In 
parallel, it is unknown whether expression of substantial quantities of LRP will alter the intracellular environment 
due to the strong positive charge of Lysine, and whether such alterations will negatively impact cellular function. 
Early studies performed by Gilad and colleagues in which LRP was expressed in cancer cells did not demonstrate 
any changes in cellular proliferation or viability18,21. Although extrapolation of this finding to non-proliferative 
cells including cardiomyocytes is not straight forward, we did not observe any detrimental effect of LRP expres-
sion on cardiac structure or function in mice. Importantly, we did not perform any experiments on isolated 
cardiac tissue to probe for markers of cellular remodeling or stress. The inclusion of experiments in which LRP 
is expressed in induced cardiomyocytes derived from human induced pluripotent stem cells would be required 
in future studies to more thoroughly evaluate the safety profile of LRP. In addition, we were unable to probe 
diastolic function or changes in systolic function with stress that manifest earlier than changes in resting systolic 
function. Future studies will examine such metrics to more thoroughly examine the impact of LRP expression of 
cardiac function. Finally, the capacity to differentially quantify a small fraction of cells expressing a therapeutic 
gene at high levels as opposed to a large fraction of cells expressing a therapeutic gene at low levels will be crucial 
for optimization of viral vector design and delivery. Since CEST contrast from LRP is generated by the exchange 
of saturated protons from LRP to the surrounding cytosol water, and the MTRasym values in each voxel represent 
the aggregate impact of all cells within the voxel, the fraction of successfully transduced cells likely dominates the 
overall CEST contrast that is observed. This is supported by comparison of the CEST-contrast measured by Gilad 
et al.18, where a bolus of LRP-expressing cells extended over several voxels, to that of Farrar et al., where only a 
sub-fraction of cells within a voxel expressed LRP22. Similarly, beyond using immuno-fluorescence to guide the 
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definition of regions of interest for analysis, we did not perform any additional quantification of transfection 
efficiency. The presence of non-specific elevation in both MTRasym and immuno-fluorescence images observed in 
negative control animals indicates that measurement of low level early transfection or persistence of low intensity 
signal over time must be further validated beyond CEST-MRI measurements. However, it is crucial that future 
studies examine the balance that exists between both components and whether this CEST-MRI approach can dif-
ferentiate the level of LRP expression within cells from the overall fraction of cells expressing LRP in a given voxel.
The ability to non-invasively and repeatedly image gene expression patterns and functional outcomes in par-
allel will serve an important role in the continued development of cardiac gene therapy. Current efforts at optimi-
zation of delivery mechanisms29,30, novel formulae for viral preparation by inclusion of different concentrations of 
empty capsids7, or targeting with tissue specific promoters34 can be aided by the inclusion of genetically encoded 
CEST-MRI reporter genes such as LRP. With the eventual development of either FDA approved versions of LRP, 
or through the use of a coupled membrane-bound reporter peptides and targeted CEST molecules35, the physi-
ologically rich data sets that can be acquired could lead to individualized planning, treatment, and follow up to 
maximize outcomes.
Materials and Methods
Generation of viral vectors. The plasmid pIRES-EGFP-LRP204 was a gift from Assaf Gilad. The plas-
mids pZac2.1 and pAdDF6 are gifts from Paul Murphy (University of Kentucky). The LRP gene was designed 
de vovo form eight 83-base-pair-long synthetic oligonucleotides18 and cloned directly into the plasmid pIRES-
EGFP (Clontech). The plasmid pAAV9 was obtained from the University of Pennsylvania Viral Core. The 
plasmid pSMPUW-IRES-EGFP and 293LTV cells were purchased from Cell Biolabs. The vector for express-
ing V5-tagged LRP204 in recombinant AAV9-serotyped adeno-associated virus was constructed by ligating 
the NheI/NotI fragment of pIRES-EGFP-LRP204 into similarly-digested pZac2.1 to create MVAp150213B. 
DNA sequencing indicated that this construct only retained a subset (50) of the lysine repeats. The full comple-
ment of repeats was restored by ligating a 690 bp NheI/BamHI fragment of pIRES-eGFP-LRP204 into similarly 
digested MVAplan150213B to create MVAp150302D1 [pAAV CMVprom::LRP204-IRES-GFP]. The V5 epitope 
was then added to the amino-terminus of LRP204 by ligating an adaptor constructed by hybridizing the oli-
gonucleotides CTAGCCACCATGGGTAAGCCTATCCCTAACCCTCTCCTCGGTCTCGATTCTACTCGAG 
and GATCCTCGAGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACCCATGGTGG into 
BglII/NheI digested MVAp150302D1 to create MVAp150506A5 [pAAV CMV > V5:200K_IRES_EGFP]. The 
vector for constructing the empty, control AAV was constructed by ligating the 1349 bp EcoRI/SalI fragment 
carrying the IRES-GFP from pSMPUW-IRES-EGFP into EcoRI/SalI-digested pZac2.1 to create ViCo1.28 
[pAAV CMVprom::LRP204-IRES-GFP]. The fidelity of each construct was confirmed by DNA sequence analysis. 
AAV9-pseudotyped viruses were prepared by co-transfecting 10 T225 culture flasks of 293LTV cells with 250 mg 
pAAV2/9, 500 mg pAdDF6 and either 250 mg of MVAp150506A5 or the empty vector, ViCo1.28 using 5 mg pol-
yethyleneimine to enhance DNA uptake. After three days, the cells were harvested, washed, suspended in 13 ml 
150 mM NaCl, 50 mM Tris·Cl pH 8.4, 0.5% deoxycholate and 50 U/ml of benzonase and incubated at 37 °C for 
30 min. An additional 2.8 ml 5 M NaCl was added and the incubation was continued for another 30 min. at 45 °C. 
The cell suspension was then subjected to four freeze/thaw cycles (30 min at −80 °C/30 min at 45 °C). The lysate 
was then partially clarified by centrifugation at 18,500 × g for 10 min at 20 °C. The supernatant was laid on top 
of an iodixanol step gradient and centrifuged at 350,000 × g for 1 hour at 18 °C. The interface between the 40% 
and 54% iodixanol layers was withdrawn and spin-purified and concentrated using four washes with PBS in an 
Amicon Ultra-15 100,000 MWCO spin concentrator. The virus preparation was then titered using quantitative 
PCR with primers directed against the CMV promoter region of the DNA encapsulated in the virions.
Administration of AAV9. A total of 45 male, 8 week old, C57B6/J mice were purchased from Jackson Labs. 
Mice were randomly assigned to either a systemic injection protocol, or a direct injection protocol. All animal 
studies adhered to the NIH guide for the care and use of laboratory animals and were approved by the Animal 
Care and Use Committee at the University of Kentucky. For systemic administration, approximately 100 μL of 
AAV9 containing LRP-V5 (n = 13), an empty AAV9 vector (n = 10), or saline (n = 7) were injected via the tail 
vein. The viral titter for both AAV9 vectors was 1.93 × 1013 genomes/mL corresponding to a dose of approxi-
mately 1.93 × 1012 genomes per injection. For the direct injection protocol 25–30 μL of either AAV9 containing 
LRP-V5 (n = 9) or an empty AAV9 vector (n = 6) were injected directly into the free wall of the left ventricle. The 
viral titter used in this arm was 2.8 × 1013 genomes/mL resulting in approximately 0.7 × 1012 viral genomes per 
injection. Intra-myocardial injection was accomplished using the pop-out technique as described by Gao et al.36. 
Briefly, mice were anesthetized using 5% isoflurane, an incision was made in the skin and the pectoralis muscles 
were separated. Afterwards, a puncture was made in the third intercostal space and the heart was gently pushed 
out of the body. A 29 g needle was inserted at the apex and advanced towards the mid-ventricle, after which the 
viral vector was injected directly into the myocardial mid-wall. The site of injection was visually confirmed by 
bleaching of the myocardium tissue at the time of injection. Afterwards, the heart was returned to the thoracic 
cavity, 8–0 suture was used to close the intercostal space, and mice were allowed to recover in room air.
Magnetic Resonance Imaging. Imaging was performed on a 7 T horizontal scanner (ClinScan, Bruker 
Biospin MRI GmbH, Ettlingen, Germany) using a cylindrical volume coil for excitation (outer diameter = 11.2 cm, 
inner diameter = 8.6 cm) and 4-channel phased array surface coil for detection. Anesthesia used 1.5% isoflurane 
in oxygen and body temperature was maintained (37 °C) using circulating water. Electrocardiogram (ECG) and 
respiratory gating used a Small Animal Instruments (SAI, Stonybrook, NY) system. The MRI pulse sequence 
used to generate CEST images has been described in detail in Pumphrey et al.24,25. The acquisition of cine images 
was electrocardiogram and respiratory gated, with dummy excitation pulses maintaining steady state conditions. 
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Imaging parameters included FOV = 2.5 × 2.5 cm, Matrix = 256 × 128, true in-plane resolution = 200 × 100 μm, 
slice thickness = 1 mm, TR/TE = 6.92/3.42 ms, 4 averages, and 15° flip angle. For CEST-saturation a train of spa-
tially non-selective Gaussian pulses (8.8 ms, 200 Hz bandwidth, 1 ms inter-pulse delay, number of pulses = 196, 
flip angle = 360°, B1average = 4 μT) were applied at offset frequencies of ± 3.76 ppm. The total acquisition time 
was 2.5–3 minutes per cine image, or 5–6 minutes per pair. For mice included in the systemic administration pro-
tocol, one mid-ventricular slice was consistently imaged at one, sixty, and ninety days post AAV9/saline admin-
istration. In the direct injection protocol one slice slightly apical to the mid-ventricle was imaged prior to AAV9 
injection. At fifteen and forty five days following AAV9 injection, three slices were imaged across a 3 mm slab 
encompassing the mid-ventricle, a slightly apical slice, and a slightly basal slice. For all protocols the distance for 
all imaged slices from the left ventricular apex and mitral valve plane were recorded at the time point of initial 
imaging and used to replicate the same slice positions over time. At the conclusion of each study mice were anes-
thetized in 5% isoflurane and perfused with saline solution for two minutes. Hearts were excised and flash frozen 
in liquid nitrogen.
Co-immunoprecipitation (Co-IP), and Western Blotting (WB). Hearts were homogenized using 
homogenization buffer containing 1 × Hsaio TBS, PMSF (1:1000), 1:1000 Protease Inhibitor cocktail set 3 (EMD 
Millipore #539134), 1:1000 PhosphotaseArrest II (GBioscience #786-451), and 1:1000 PhosphotaseArrest III 
(GBioscience #786-452). Samples were centrifuged at 10,000 rpm and supernatant was isolated. Protein superna-
tant concentration was determined using BCA (Thermo #23225). Samples were incubated with anti-V5 antibody 
(Abcam #ab184144) at 1:1000 overnight at 4 °C. G-protein beads were then incubated with samples for 4 hours. 
Samples were centrifuged at 3000 rpm and beads were isolated. Beads were washed twice and centrifuged at 
3000 rpm. Beads were centrifuged at 10,000 rpm and supernatant was entirely removed. Beads were then resus-
pended in 2× Laemmli Buffer with beta-mercaptoethanol. Samples were run on 10% Tris-Glycine gels (BioRad 
#5671034), and transferred to PVDF membranes (EMD Millipore #IPVH00010). Primary antibodies used were 
Anti-V5 antibody (Abcam #ab184144) at 1:1000 and Actinin (Sigma-Aldrich #A2066) at 1:1000. Protein signals 
were revealed by ECL (Pierce #32106) using a GE Amersham Imager 600UV system. Image analysis was per-
formed using ImageJ. Bands of interest were normalized to a loading control. Statistical analysis of the bands was 
performed using Student’s t-test in GraphPad Prism.
Immunofluorescence. Immunofluorescent staining was performed on 6–10 axial heart slices spanning the 
left ventricle using a previously described protocol37. Briefly, tissue was mounted in 30% ethanol on ColorFrost 
Plus slides (Thermo, cat# 9951APLUS-006) and then blocked in blocking buffer (10% normal goat serum, 0.2% 
Triton X-100, 0.02% 10% sodium azide in 1X tris buffered saline). Primary antibodies were suspended in block-
ing buffer and incubated at 4 degrees Celsius overnight. Slides were then washed and incubated in secondary 
antibodies (Alexafluor Goat anti-Rabbit 594 #A11037, Alexafluor Goat anti-Mouse 488 #A11029). Slides were 
coverslipped and then imaged. Primary antibodies used were Anti-V5 antibody (Abcam #ab184144) at 1:100.
Microscopy. A BioTek Cytation5 Imaging Multi Mode Reader was used to capture images of stained hearts. 
All immunolabeling acquisition intensities and microscope settings were kept consistent across all images. 
Montage scans were taken of entire heart sections within similar regions. Images were prepared using Photoshop 
Cs6 (Adobe) and Illustrator Cs6 (Adobe).
MRI Data Analysis. Data analysis was performed in MATLAB R2012b (Mathworks, Nattick, MA) using cus-
tom built software. For each mouse and time point the end-diastolic image acquired following saturation at 3.76 
ppm was registered to the corresponding image acquired following saturation at −3.76 ppm. Maps of the asym-
metric magnetization transfer ratio (MTRasym) were then calculated on a voxel-wise basis as MTRasym = (S−3.76ppm − 
S3.76ppm)/S−3.76ppm * 100. Endocardial and epicardial borders of the myocardium were defined using images 
acquired following saturation at −3.76 ppm. The average myocardial MTRasym value was measured for the sys-
temic administration protocol. For analysis of data generated from mice in the direct injection model receiving 
AAV9-LRP-V5, the mean MTRasym value across a region of interest defined as V5-positive based on the matching 
mid-ventricular immunofluorescence staining pattern was measured. For mice receiving empty AAV9, the mean 
MTRasym value along the area of the LV free wall about the needle track from H&E stained images was measured. 
Across all mice, fractional shortening was measured at the mid-ventricle as FS = (diastolic diameter − systolic 
diameter)/diastolic diameter. The ratio of septal wall thickness to chamber radius was also measured at the mid 
ventricle. For all figures shown, maps of MTRasym are processed such that only voxels from the left ventricle are 
superimposed upon corresponding magnitude reconstructed images.
Statistical Analysis. Statistical analysis was performed in SigmaPlot v13 (Systat, San Jose, CA). Two way 
analysis of variance (ANOVA) tests were used to assess differences in MTRasym, cardiac structure and func-
tion, and heart rate between groups of mice at each time point and within groups of mice across time points. 
Holm-Sidak was used for pairwise comparison. Unless otherwise noted all data was normally distributed. 
Statistical significance was defined as p < 0.05. Data is graphically represented throughout the manuscript 
using box and whisker plots. In places where data is numerically represented, the mean ± standard deviation is 
presented.
Data and materials availability. All data is maintained on a server at UC Berkeley and will be made avail-
able to interested researchers upon request. Interested parties should contact corresponding author.
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